Modulation of α


Journal

Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880

Informations de publication

Date de publication:
02 2021
Historique:
received: 07 07 2020
accepted: 16 11 2020
revised: 16 11 2020
pubmed: 3 2 2021
medline: 19 2 2022
entrez: 2 2 2021
Statut: ppublish

Résumé

Osteoarthritis is characterized by structural alteration of joints. Fibrosis of the synovial tissue is often detected and considered one of the main causes of joint stiffness and pain. In our earlier proteomic study, increased levels of vitronectin (VTN) fragment (amino acids 381-397) were observed in the serum of osteoarthritis patients. In this work, the affinity of this fragment for integrins and its putative role in TGF-β1 activation were investigated. A competition study determined the interaction of VTN

Identifiants

pubmed: 33526813
doi: 10.1038/s12276-021-00558-2
pii: 10.1038/s12276-021-00558-2
pmc: PMC8080589
doi:

Substances chimiques

Antigens, Neoplasm 0
Biomarkers 0
Inflammation Mediators 0
Integrins 0
Peptides 0
Transforming Growth Factor beta1 0
Vitronectin 0
integrin alphavbeta6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

210-222

Références

Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745–1759 (2019).
pubmed: 31034380 doi: 10.1016/S0140-6736(19)30417-9
Vina, E. R. & Kwoh, C. K. Epidemiology of osteoarthritis: literature update. Curr. Opin. Rheumatol. 30, 160–167 (2018).
pubmed: 29227353 pmcid: 5832048 doi: 10.1097/BOR.0000000000000479
Scanzello, C. R. & Goldring, S. R. The role of synovitis in osteoarthritis pathogenesis. Bone 51, 249–257 (2012).
pubmed: 22387238 pmcid: 3372675 doi: 10.1016/j.bone.2012.02.012
Mathiessen, A. & Conaghan, P. G. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res. Ther. 19, 18 (2017).
pubmed: 28148295 pmcid: 5289060 doi: 10.1186/s13075-017-1229-9
Deroyer, C. et al. CEMIP (KIAA1199) induces a fibrosis-like process in osteoarthritic chondrocytes. Cell Death Dis. 10, 103 (2019).
pubmed: 30718510 pmcid: 6362103 doi: 10.1038/s41419-019-1377-8
Remst, D. F., Blaney Davidson, E. N. & van der Kraan, P. M. Unravelling osteoarthritis-related synovial fibrosis: a step closer to solving joint stiffness. Rheumatology 54, 1954–1963 (2015).
pubmed: 26175472 doi: 10.1093/rheumatology/kev228
Steenvoorden, M. M. et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res. Ther. 8, R165 (2006).
pubmed: 17076892 pmcid: 1794508 doi: 10.1186/ar2073
Hayashi, H. & Sakai, T. Biological significance of local TGF-β activation in liver diseases. Front. Physiol. 3, 12 (2012).
pubmed: 22363291 pmcid: 3277268 doi: 10.3389/fphys.2012.00012
Koivisto, L., Bi, J., Häkkinen, L. & Larjava, H. Integrin αvβ6: Structure, function and role in health and disease. Int. J. Biochem. Cell Biol. 99, 186–196 (2018).
pubmed: 29678785 doi: 10.1016/j.biocel.2018.04.013
Kalli, A. C., Rog, T., Vattulainen, I., Campbell, I. D. & Sansom, M. S. P. The integrin receptor in biologically relevant bilayers: insights from molecular dynamics simulations. J. Membr. Biol. 250, 337–351 (2017).
pubmed: 27465729 doi: 10.1007/s00232-016-9908-z
Charlier, E. et al. Toward diagnostic relevance of the αVβ5, αVβ3, and αVβ6 integrins in OA: expression within human cartilage and spinal osteophytes. Bone Res. 8, 35 (2020).
pubmed: 33083095 pmcid: 7527564 doi: 10.1038/s41413-020-00110-4
Hynes, R. O. Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687 (2002).
pubmed: 12297042 doi: 10.1016/S0092-8674(02)00971-6
Munger, J. S. et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).
pubmed: 10025398 doi: 10.1016/S0092-8674(00)80545-0
Henderson, N. C. & Sheppard, D. Integrin-mediated regulation of TGFβ in fibrosis. Biochim. Biophys. Acta 1832, 891–896 (2013).
pubmed: 23046811 doi: 10.1016/j.bbadis.2012.10.005
de Seny, D. et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann. Rheum. Dis. 70, 1144–1152 (2011).
pubmed: 21362709 doi: 10.1136/ard.2010.135541
Naik, M. U. & Naik, U. P. Junctional adhesion molecule-A-induced endothelial cell migration on vitronectin is integrin alpha v beta 3 specific. J. Cell Sci. 119, 490–499 (2006).
pubmed: 16418218 doi: 10.1242/jcs.02771
Preissner, K. T. & Reuning, U. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin. Thromb. Hemost. 37, 408–424 (2011).
pubmed: 21805447 doi: 10.1055/s-0031-1276590
Shen, T. L. et al. The positive role of vitronectin in radiation induced lung toxicity: the in vitro and in vivo mechanism study. J. Transl. Med. 16, 100 (2018).
pubmed: 29661186 pmcid: 5902986 doi: 10.1186/s12967-018-1474-y
Tian, J., Zhang, F. J. & Lei, G. H. Role of integrins and their ligands in osteoarthritic cartilage. Rheumatol. Int. 35, 787–798 (2015).
pubmed: 25261047 doi: 10.1007/s00296-014-3137-5
Hayashida, M., Hashimoto, K., Ishikawa, T. & Miyamoto, Y. Vitronectin deficiency attenuates hepatic fibrosis in a non-alcoholic steatohepatitis-induced mouse model. Int. J. Exp. Pathol. 100, 72–82 (2019).
pubmed: 30887659 pmcid: 6540715 doi: 10.1111/iep.12306
Gundogdu, B., Yolbas, S., Yilmaz, M., Aydin, S. & Koca, S. S. Serum osteopontin and vitronectin levels in systemic sclerosis. Adv. Clin. Exp. Med. 26, 1231–1236 (2017).
pubmed: 29264880 doi: 10.17219/acem/68627
Chain, D., Kreizman, T., Shapira, H. & Shaltiel, S. Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett. 285, 251–256 (1991).
pubmed: 1713175 doi: 10.1016/0014-5793(91)80810-P
Zhong, J. et al. Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts. Lab. Investig. 94, 633–644 (2014).
pubmed: 24687120 doi: 10.1038/labinvest.2014.51
Relic, B. et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J. Biol. Chem. 279, 22399–22403 (2004).
pubmed: 15004016 doi: 10.1074/jbc.M314118200
Sengupta, S. et al. Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 12, 837–847 (2010).
pubmed: 20927322 pmcid: 2950333 doi: 10.1593/neo.10662
Ning, S., Nemeth, J. A., Hanson, R. L., Forsythe, K. & Knox, S. J. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol. Cancer Ther. 7, 1569–1578 (2008).
pubmed: 18566227 doi: 10.1158/1535-7163.MCT-08-0288
Tak, P. P. et al. Expression of adhesion molecules in early rheumatoid synovial tissue. Clin. Immunol. Immunopathol. 77, 236–242 (1995).
pubmed: 7586733 doi: 10.1006/clin.1995.1149
Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).
pubmed: 29203879 pmcid: 5715110 doi: 10.1038/s41598-017-17204-5
Abe, M. et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 216, 276–284 (1994).
pubmed: 8179182 doi: 10.1006/abio.1994.1042
Annes, J. P., Chen, Y., Munger, J. S. & Rifkin, D. B. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J. Cell Biol. 165, 723–734 (2004).
pubmed: 15184403 pmcid: 2172370 doi: 10.1083/jcb.200312172
Cobraiville, G. et al. Validation of a new method by nano-liquid chromatography on chip tandem mass spectrometry for combined quantitation of C3f and the V65 vitronectin fragment as biomarkers of diagnosis and severity of osteoarthritis. Talanta 169, 170–180 (2017).
pubmed: 28411808 doi: 10.1016/j.talanta.2017.03.078
Maile, L. A. et al. The heparin binding domain of VTN is the region that is required to enhance insulin-like growth factor-I signaling. Mol. Endocrinol. 20, 881–892 (2006).
pubmed: 16322097 doi: 10.1210/me.2005-0382
Maile, L. A. et al. Modulation of integrin antagonist signaling by ligand binding of the heparin-binding domain of VTN to the alphaVbeta3 integrin. J. Cell. Biochem. 105, 437–446 (2008).
pubmed: 18615592 pmcid: 2659671 doi: 10.1002/jcb.21841
Vaamonde-Garcia, C. et al. 15-Deoxy-Δ-12, 14-prostaglandin J2 acts cooperatively with prednisolone to reduce TGF-β-induced pro-fibrotic pathways in human osteoarthritis fibroblasts. Biochem. Pharmacol. 165, 66–78 (2019).
pubmed: 30936016 doi: 10.1016/j.bcp.2019.03.039
Robertson, I. B. & Rifkin, D. B. Regulation of the bioavailability of TGF-β and TGF-β-related proteins. Cold Spring Harb. Perspect. Biol. 8, a021907 (2016).
pubmed: 27252363 pmcid: 4888822 doi: 10.1101/cshperspect.a021907
Montaldo, C. et al. Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic iron overload. Proteomics 14, 1107–1115 (2014).
pubmed: 24616218 doi: 10.1002/pmic.201300422
Tsuruta, Y., Park, Y. J., Siegal, G. P., Liu, G. & Abraham, E. Involvement of vitronectin in lipopolysaccaride-induced acute lung injury. J. Immunol. 179, 7079–7086 (2007).
pubmed: 17982099 doi: 10.4049/jimmunol.179.10.7079
Preissner, K. T. The role of vitronectin as multifunctional regulator in the hemostatic and immune systems. Blut 59, 419–431 (1989).
pubmed: 2479432 doi: 10.1007/BF00349063
Bae, H. B. et al. Vitronectin inhibits neutrophil apoptosis through activation of integrin-associated signaling pathways. Am. J. Respir. Cell Mol. Biol. 46, 790–796 (2012).
pubmed: 22281987 pmcid: 3380283 doi: 10.1165/rcmb.2011-0187OC
Singh, B., Janardhan, K. S. & Kanthan, R. Expression of angiostatin, integrin alphavbeta3, and vitronectin in human lungs in sepsis. Exp. Lung Res. 31, 771–782 (2005).
pubmed: 16368651 doi: 10.1080/01902140500324901
Tomasini-Johansson, B. R., Milbrink, J. & Pejler, G. Vitronectin expression in rheumatoid arthritic synovia-inhibition of plasmin generation by vitronectin produced in vitro. Br. J. Rheumatol. 37, 620–629 (1998).
pubmed: 9667615 doi: 10.1093/rheumatology/37.6.620
Reilly, J. T. & Nash, J. R. Vitronectin (serum spreading factor): its localisation in normal and fibrotic tissue. J. Clin. Pathol. 41, 1269–1272 (1988).
pubmed: 2465316 pmcid: 1141758 doi: 10.1136/jcp.41.12.1269
Koukoulis, G. K., Shen, J., Virtanen, I. & Gould, V. E. Vitronectin in the cirrhotic liver: an immunomarker of mature fibrosis. Hum. Pathol. 32, 1356–1362 (2001).
pubmed: 11774169 doi: 10.1053/hupa.2001.29675
Courey, A. J. et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 118, 2313–2321 (2011).
pubmed: 21734232 pmcid: 3162358 doi: 10.1182/blood-2010-12-324574
Bandyopadhyay, A. & Raghavan, S. Defining the role of integrin alphavbeta6 in cancer. Curr. Drug Targets 10, 645–652 (2009).
pubmed: 19601768 pmcid: 2888263 doi: 10.2174/138945009788680374
Landen, C. N. et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10, 1259–1267 (2008).
pubmed: 18953435 pmcid: 2570602 doi: 10.1593/neo.08740
Horton, M. A. The alpha v beta 3 integrin “vitronectin receptor”. Int. J. Biochem. Cell Biol. 29, 721–725 (1997).
pubmed: 9251239 doi: 10.1016/S1357-2725(96)00155-0
Hapke, S. et al. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem. 276, 26340–26348 (2001).
pubmed: 11331280 doi: 10.1074/jbc.M100181200
Horan, G. S. et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177, 56–65 (2008).
pubmed: 17916809 doi: 10.1164/rccm.200706-805OC
Popov, Y. et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 48, 453–464 (2008).
pubmed: 18221819 doi: 10.1016/j.jhep.2007.11.021
Schnittert, J., Bansal, R., Storm, G. & Prakash, J. Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Adv. Drug Deliv. Rev. 129, 37–53 (2018).
pubmed: 29414674 doi: 10.1016/j.addr.2018.01.020
Nam, E. J. et al. Up-regulated transforming growth factor beta-inducible gene h3 in rheumatoid arthritis mediates adhesion and migration of synoviocytes through alpha v beta3 integrin: regulation by cytokines. Arthritis Rheum. 54, 2734–2744 (2006).
pubmed: 16947382 doi: 10.1002/art.22076
Sullivan, B. P., Kassel, K. M., Manley, S., Baker, A. K. & Luyendyk, J. P. Regulation of transforming growth factor-β1-dependent integrin β6 expression by p38 mitogen-activated protein kinase in bile duct epithelial cells. J. Pharmacol. Exp. Ther. 337, 471–478 (2011).
pubmed: 21303922 pmcid: 3083106 doi: 10.1124/jpet.110.177337
Margadant, C. & Sonnenberg, A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97–105 (2010).
pubmed: 20075988 pmcid: 2828749 doi: 10.1038/embor.2009.276
Kim, K. K., Sheppard, D. & Chapman, H. A. TGF-β1 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10, a022293 (2018).
pubmed: 28432134 pmcid: 5880172 doi: 10.1101/cshperspect.a022293
Nolte, M. A. & Margadant, C. Controlling immunity and inflammation through integrin-dependent regulation of TGF-β. Trends Cell Biol. 30, 49–59 (2020).
pubmed: 31744661 doi: 10.1016/j.tcb.2019.10.002
McCarty, J. H. αvβ8 integrin adhesion and signaling pathways in development, physiology and disease. J. Cell Sci. 133, jcs239434 (2020).
pubmed: 32540905 doi: 10.1242/jcs.239434 pmcid: 7328133
Lygoe, K. A., Wall, I., Stephens, P. & Lewis, M. P. Role of vitronectin and fibronectin receptors in oral mucosal and dermal myofibroblast differentiation. Biol. Cell 99, 601–614 (2007).
pubmed: 17516912 doi: 10.1042/BC20070008
Schuliga, M., Grainge, C., Westall, G. & Knight, D. The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. Int. J. Biochem. Cell Biol. 97, 108–117 (2018).
pubmed: 29474926 doi: 10.1016/j.biocel.2018.02.016

Auteurs

Federica Ciregia (F)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium. federica.ciregia@uliege.be.

Céline Deroyer (C)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium.

Gaël Cobraiville (G)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium.

Zelda Plener (Z)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium.

Olivier Malaise (O)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium.

Philippe Gillet (P)

Department of Orthopedic Surgery, University Hospital Sart-Tilman, Liege, Belgium.

Marianne Fillet (M)

Laboratory for the Analysis of Medicines, CIRM, Department of Pharmacy, University of Liège, Liège, Belgium.

Michel G Malaise (MG)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium.

Dominique de Seny (D)

Laboratory of Rheumatology, GIGA-I3, University of Liège, CHU de Liège, Liège, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH